Company intelligence / Profile preview

Halodine

Spring House, Pennsylvania, United Stateshalodine.com ↗

Ownership: Private
Development stage: Commercial

Overview

Halodine has developed proprietary nasal and oral antiseptics that have demonstrated rapid inactivation of SARS-CoV-2, the virus responsible for COVID‑19, in less than 15 seconds. The products are marketed as providing up to 4 hours of protection, with clinical validation against SARS-CoV‑2. Ongoing collaborations aim to expand efficacy data against other clinically important pathogens, including drug-resistant hospital-acquired infections[1][2][3].

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeAntiseptic (topical)
Industry: Biotech

Drug pipeline

1 asset

Halodine

Partnerships

Emery Pharma[3][6]

Beyond the preview

Go deeper on Halodine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halodine.

Explore the full profile